As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil Corp. (XOM) and Costco Wholesale Corp. (COST), as well a micro-cap stock ...

In this article, we are going to take a look at where Eli Lilly and Company ... the third quarter of 2024, the company received product approvals and launched new pipeline data for crucial ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ... Pavlik shared that as the new administration takes over he is optimistic about how ...

In this article, we are going to take a look at where Eli Lilly And ... is turned into two new shares. This makes each share half the price, but the total value of the company remains the same.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE ... In a 2-for-1 split, each share is turned into two new shares. This makes each share half the price, but the total ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.